A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
33actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-09 | actual | When the study began enrolling |
| Primary completion | 2025-09-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-22 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Sickle Cell Disease
- Thalassemia
Interventions
- Drug: Etavopivat
- Drug: Moxifloxacin
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Number of treatment-emergent adverse events (AEs)
measured From dosing (Day 1) until end of study (Day 8)
Part B: Change from baseline in Fridericia heart rate corrected QT interval (ΔQTcF) for etavopivat
measured From pre-dose to post etavopivat/ etavopivat placebo dose on day 1 to day 23
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed